Almac

The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.

The collaboration will streamline patient sample analysis to determine whether they should be included in clinical trials for molecularly targeted treatment. 

The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.

The deal allows UK-based Almac to develop NGS assays on the Illumina MiSeqDx instrument.

The firms are developing a gene expression RSPO3 CLIA assay to select patients in the clinical development of OncoMed's therapeutic.

NEW YORK (GenomeWeb) — Pharmaceutical companies are jockeying to formulate companion diagnostics strategies that involve a new microarray-based assay developed by Almac Diagnostics, according to the company.

NEW YORK (GenomeWeb) — Almac Diagnostics has developed a microarray-based test that can be used to determine which ovarian cancer patients will have a good prognosis following chemotherapy.

NEW YORK (GenomeWeb News) – Almac's diagnostics business today said that it has received a clinical laboratory permit from New York, allowing it to receive clinical samples from the state for clinical testing and trial management.

Almac Diagnostics said this week that a group led by partner Precision Therapeutics has independently validated Almac's ColDx test for stage II colorectal cancer recurrence ahead of its full commercialization in the US.

Pages

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.